Blair William & Co. IL Sells 53,430 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Blair William & Co. IL trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 14.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 304,381 shares of the medical research company’s stock after selling 53,430 shares during the period. Blair William & Co. IL owned about 0.16% of Exact Sciences worth $17,103,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Asset Planning Inc purchased a new position in Exact Sciences during the 4th quarter valued at $40,000. Modus Advisors LLC bought a new position in Exact Sciences in the fourth quarter worth about $43,000. AlphaQuest LLC lifted its holdings in Exact Sciences by 22,825.0% in the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after buying an additional 913 shares during the period. SBI Securities Co. Ltd. bought a new stake in Exact Sciences during the 4th quarter valued at approximately $66,000. Finally, Kieckhefer Group LLC purchased a new position in shares of Exact Sciences during the 4th quarter worth approximately $188,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Exact Sciences Stock Down 3.0 %

Shares of Exact Sciences stock opened at $43.66 on Friday. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The company’s 50 day moving average is $49.71 and its 200 day moving average is $57.80. The company has a market cap of $8.11 billion, a price-to-earnings ratio of -7.84 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. The company had revenue of $713.42 million during the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Research analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Bank of America lowered their target price on Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Piper Sandler dropped their target price on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Royal Bank of Canada initiated coverage on shares of Exact Sciences in a research note on Thursday, March 13th. They issued a “sector perform” rating and a $52.00 price target for the company. Guggenheim set a $60.00 price objective on shares of Exact Sciences and gave the stock a “buy” rating in a research note on Friday. Finally, Barclays lowered their target price on shares of Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Two investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $70.26.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.